AstraZeneca Falls On Downgrade In Rating

Shares of AstraZeneca Plc AZN moved down in pre-market trading after Royal Bank of Scotland downgraded the company. RBS downgraded AZN from “buy” to “hold.” The broker said, "AstraZeneca had a strong run of positive news flow over the summer and the near-term share price drivers have played out. AstraZeneca is within 10% of our target price and we lower our recommendation to hold." AZN shares dropped 0.88% to $51.56 in pre-market trading. More Analyst Ratings here